Clinical study of combined application of indocyanine green and methylene blue for sentinel lymph node biopsy in breast cancer

What Was Tested

This randomized controlled trial paper looks at Methylene blue (non-peptide stack partner).

This study aims to investigate the feasibility of combined application of indocyanine green (ICG) and methylene blue (MB) for sentinel lymph node biopsy (SLNB) in patients with early breast cancer.

Who Took Part

The study group was 415 patients.

PubMed indexes the participants as adults, middle-aged adults and older adults, women only.

A total of 415 patients who underwent SLNB and axillary lymph node dissection were enrolled.

Sentinel lymph node (SLN) was assessed in 197 patients with ICG and MB combination method, while, the other 218 patients were detected by MB method alone.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.

During surgery, all SLNs were harvested for pathological examination.

Then the detection rate and false negative rate of SLNs were comparatively analyzed between the 2 groups.

What Was Measured

Topics PubMed links to this paper include Breast Neoplasms, Coloring Agents, False Negative Reactions, Indocyanine Green, Methylene Blue, Neoplasm Staging and Sensitivity and Specificity.

What This Means in Plain Language

The paper is a randomized study of Methylene blue (non-peptide stack partner) in 415 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (Medicine), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.